Oppenheimer set a $120.00 target price on Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Monday morning. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ FY2021 earnings at $7.03 EPS and FY2022 earnings at $7.88 EPS.
Several other research analysts have also commented on the company. ValuEngine raised Neurocrine Biosciences from a hold rating to a buy rating in a research report on Monday, April 2nd. BidaskClub downgraded Neurocrine Biosciences from a strong-buy rating to a buy rating in a research note on Tuesday, March 20th. Leerink Swann boosted their target price on Neurocrine Biosciences from $90.00 to $96.00 and gave the stock an outperform rating in a research note on Tuesday, February 20th. JPMorgan Chase boosted their target price on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an overweight rating in a research note on Wednesday, February 14th. Finally, Barclays restated an overweight rating and set a $100.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, February 14th. Thirteen analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $102.77.
Get Neurocrine Biosciences alerts:
Neurocrine Biosciences opened at $92.49 on Monday, according to Marketbeat.com. The firm has a market capitalization of $8.35 billion, a PE ratio of -57.09 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a current ratio of 11.06 and a quick ratio of 11.06. Neurocrine Biosciences has a 12 month low of $92.60 and a 12 month high of $94.19.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, April 30th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.18). The company had revenue of $71.08 million during the quarter, compared to the consensus estimate of $65.17 million. Neurocrine Biosciences had a negative return on equity of 29.67% and a negative net margin of 45.56%. During the same period in the previous year, the firm posted ($0.90) earnings per share. research analysts expect that Neurocrine Biosciences will post -0.24 earnings per share for the current year.
In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 126,832 shares of the business’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $80.75, for a total transaction of $10,241,684.00. Following the sale, the chief executive officer now owns 473,865 shares in the company, valued at approximately $38,264,598.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Corinne H. Nevinny sold 5,000 shares of the business’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $83.13, for a total value of $415,650.00. Following the sale, the director now owns 43,283 shares in the company, valued at approximately $3,598,115.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 207,705 shares of company stock worth $17,485,904. Company insiders own 4.30% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC grew its stake in Neurocrine Biosciences by 7.5% during the 4th quarter. Perceptive Advisors LLC now owns 5,151,589 shares of the company’s stock valued at $399,712,000 after purchasing an additional 360,000 shares during the last quarter. BlackRock Inc. grew its stake in Neurocrine Biosciences by 2.8% during the 1st quarter. BlackRock Inc. now owns 4,908,495 shares of the company’s stock valued at $407,061,000 after purchasing an additional 132,749 shares during the last quarter. TimesSquare Capital Management LLC grew its stake in Neurocrine Biosciences by 0.9% during the 4th quarter. TimesSquare Capital Management LLC now owns 2,370,050 shares of the company’s stock valued at $183,892,000 after purchasing an additional 21,950 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in Neurocrine Biosciences by 50.3% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,966,109 shares of the company’s stock valued at $163,049,000 after purchasing an additional 657,712 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in Neurocrine Biosciences by 2.1% during the 4th quarter. Wells Fargo & Company MN now owns 965,449 shares of the company’s stock valued at $74,909,000 after purchasing an additional 20,081 shares during the last quarter.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.